Mosunetuzumab for CLL MRD Clearance

NCT07052695 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Inhye Ahn

Collaborators